Benefytt (BFYT) SC 13DHealth Insurance Innovations, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No.  )¹

Health Insurance Innovations, Inc.

(Name of Issuer)

Class A Common Stock, $0.001 par value

(Title of Class of Securities)

42225K106

(CUSIP Number)

Voss Capital, LLC

3773 Richmond, Suite 500

Houston, Texas 77046

(212) 721-0494

ANDREW FREEDMAN, ESQ.

OLSHAN FROME WOLOSKY LLP

1325 Avenue of the Americas

New York, New York 10019

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

December 23, 2019

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box☒.

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,see theNotes).

* Includes 46,400Shares underlying certain call options exercisable within sixty days hereof.

* Includes 46,400Shares underlying certain call options exercisable within sixty days hereof.

* Includes 46,400Shares underlying certain call options exercisable within sixty days hereof.

* Includes 46,400Shares underlying certain call options exercisable within sixty days hereof.

* Includes 46,400Shares underlying certain call options exercisable within sixty days hereof.

The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”). Prior to filing the Schedule 13D, the Reporting Persons (defined below) had relied on Rule 13d-1(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which provides that a Schedule 13G shall be filed within 45 days after the end of the calendar year in which the person became obligated under Rule 13d-1(b).

This statement relates to the Class A Common Stock, $0.001 par value per share (the “Shares”), of Health Insurance Innovations, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 15438 North Florida Avenue, Suite 201, Tampa, Florida 33613.

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

(b)       The address of the principal office of each of the Reporting Persons is 3773 Richmond, Suite 500, Houston, Texas 77046.

(c)       The principal business of Voss Value Fund is investing in securities. The principal business of Voss Advisors is serving as the general partner of Voss Value Fund. The principal business of Voss GP is serving as the general partner of Voss Advisors. The principal business of Voss Capital is serving as the investment manager of each of Voss Value Fund and the Voss Managed Account. Mr. Cocke serves as the managing member of each of Voss Capital and Voss GP.

(d)       No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)       No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)       Voss Value Fund, Voss Advisors, Voss GP and Voss Capital are organized under the laws of the State of Texas. Mr. Cocke is a citizen of the United States of America.

The Shares purchased by Voss Value Fund and held in the Voss Managed Account were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market transactions. The aggregate purchase price of the 762,141 Shares beneficially owned by Voss Value Fund is approximately $16,664,950, including brokerage commissions. The aggregate purchase price of certain call options exercisable into 46,400 Shares that may be deemed to be beneficially owned by Voss Value Fund, as further described in Item 6 below, is approximately $83,102, including brokerage commissions. The aggregate purchase price of the 474,568 Shares held in the Voss Managed Account is approximately $10,220,477, including brokerage commissions.

The Reporting Persons purchased the Shares based on the Reporting Persons’ belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

The Reporting Persons believe that the Issuer is one of the most misunderstood companies in the public markets. The Reporting Persons believe that the Issuer’s Shares are deeply undervalued and do not reflect the high quality of its business, its leading position in the industry, and the Issuer’s potential for long-term revenue, earnings and cash flow growth.

As the Issuer’s individual and family plan (“IFP”) business goes into partial run-off, throwing off prodigious free cash flow in 2020 and beyond, the Reporting Persons believe that the IFP business alone is worth at least $250 million due to the conservatively marked contract assets on the balance sheet. The Reporting Persons are encouraged to hear the Issuer reiterate its commitment to investing in and growing its promising Medicare business. The Issuer’s most direct trading comparable, eHealth Inc. (“EHTH”) (NASDAQ: EHTH), is valued 4.5x 2020 revenue estimates. If the Issuer were to generate close to $150 - $200 million of Medicare related revenue in 2020 and were ascribed EHTH’s 4.5x forward revenue multiple (despite growing even faster than EHTH and being more profitable), that segment alone would be worth multiples of the current Share price.

The M&A environment in the insurance technology and brokerage space has rarely been more active than it is today with numerous well capitalized private equity firms and strategic acquirers buying similar businesses at valuation multiples above 4.0x EV/Sales. The table below shows precedent transactions that have occurred just within the last eight months.

The Reporting Persons understand the Board of Directors’ (the “Board”) desire to take advantage of this environment of active M&A and the Reporting Persons intend to help management unlock the substantial embedded value for all stockholders.

No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the Board to discuss their views, including the composition of the Board and corporate governance practices, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Persons’ investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer’s financial and/or operational performance, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing their intention with respect to any and all matters referred to in Item 4.

The aggregate percentage of Shares reported owned by each person named herein is based upon 12,296,567 Shares outstanding, as of November 8, 2019, which is the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019.

Percentage: Approximately 6.6%

Percentage: Approximately 6.6%

Percentage: Approximately 6.6%

Percentage: Approximately 10.4%

Percentage: Approximately 10.4%

The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Exchange Act, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

Voss Value Fund sold exchange-listed American-style call options referencing 4,800 Shares, which have an exercise price of $19 and expire on January 17, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund purchased exchange-listed American-style call options referencing 35,000 Shares, which have an exercise price of $25 and expire on January 17, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund sold exchange-listed American-style put options referencing an aggregate of 15,000 Shares and 10,000 Shares, which have an exercise price of $20 and $26, respectively, and expire on January 17, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund sold exchange-listed American-style call options referencing an aggregate of 10,000, 21,700 Shares and 5,000 Shares, which have an exercise price of $16, $18 and $21, respectively, and expire on February 21, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund purchased exchange-listed American-style call options referencing 1,400 Shares, which have an exercise price of $34 and expire on February 21, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund sold exchange-listed American-style put options referencing an aggregate of 2,400 Shares, 15,000 Shares, 20,000 Shares, 10,000 Shares and 10,000 Shares, which have an exercise price of $13, $15, $18, $20 and $22, respectively, and expire on February 21, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Capital through the Voss Managed Account sold exchange-listed American-style put options referencing an aggregate of 4,000 Shares, which have an exercise price of $23, and expire on February 21, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund purchased exchange-listed American-style call options referencing 10,000 Shares, which have an exercise price of $10 and expire on May 15, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund sold exchange-listed American-style call options referencing an aggregate of 10,000 Shares, 20,000 Shares and 10,000 Shares, which have an exercise price of $17, $19, and $21, respectively, and expire on May 15, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund sold exchange-listed American-style put options referencing an aggregate of 10,000 Shares, 10,000 Shares and 10,00 Shares, which have an exercise price of $14, $19 and $23, respectively, and expire on May 15, 2020, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund sold exchange-listed American-style call options referencing an aggregate of 20,000 Shares, 15,000 Shares and 2,400 Shares, which have an exercise price of $18, $22 and $30, respectively, and expire on January 15, 2021, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund sold exchange-listed American-style put options referencing an aggregate of 10,000 Shares, 10,000 Shares and 10,000 Shares, which have an exercise price of $10, $15 and $22, respectively, and expire on January 15, 2021, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Capital through the Voss Managed Account sold exchange-listed American-style put options referencing an aggregate of 3,900 Shares, which have an exercise price of $25, and expire on January 21, 2022, as further detailed in Schedule A, which is incorporated herein by reference.

Voss Value Fund sold exchange-listed American-style call options referencing an aggregate of 10,000 Shares, which have an exercise price of $25, and expire on January 21, 2022, as further detailed in Schedule A, which is incorporated herein by reference.

On December 23, 2019, the Reporting Persons entered into a Joint Filing Agreement. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: December 23, 2019

Schedule A

Transactions in the Shares During the Past Sixty Days

Voss Value Fund, L.P.

VOSS CAPITAL, LLC

(Through the Voss Managed Account)

¹ Represents shares underlying exchange-listed American-style call options. These call options expire on February 21, 2020.

² Represents shares underlying exchange-listed American-style call options. These call options expire on January 17, 2020.

³ Represents shares underlying exchange-listed American-style put options. These put options had an expiration date of December 20, 2019.

⁴ Represents shares underlying exchange-listed American-style put options. These put options had an expiration date of November 15, 2019.

⁵ Represents shares underlying exchange-listed American-style call options. These call options had an expiration date of November 15, 2019.

⁶ Represents shares underlying exchange-listed American-style call options. These call options had an expiration date of December 20, 2019.

⁷ Represents shares underlying exchange-listed American-style put options. These put options expire on January 17, 2020.

⁸ Represents shares underlying exchange-listed American-style put options. These put options expire on February 21, 2020.

⁹ Represents shares underlying exchange-listed American-style put options. These put options expire on January 15, 2021.

¹⁰ Represents shares underlying exchange-listed American-style call options. These call options expire on January 15, 2021.

¹¹ Represents shares underlying exchange-listed American-style call options. These call options expire on May 15, 2021.

¹² Represents shares underlying exchange-listed American-style call options. These call options expire on January 21, 2022.

¹³ Represents shares underlying exchange-listed American-style put options. These put options expire on January 21, 2022.